Anti‐programmed cell death‐1 therapy in nonmelanoma skin cancer-Reference-Cited by-同舟云学术

Anti‐programmed cell death‐1 therapy in nonmelanoma skin cancer

Published:2016-10-17 Issue:2 Volume:176 Page:498-502
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Winkler J.K.¹,Schneiderbauer R.¹,Bender C.¹,Sedlaczek O.²,Fröhling S.³⁴,Penzel R.⁵,Enk A.¹,Hassel J.C.¹

Affiliation:

1. Department of Dermatology and National Center for Tumor Diseases (NCT) University Hospital Heidelberg Heidelberg Germany

2. National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ) Department of Diagnostic Radiology University Hospital Heidelberg Heidelberg Germany

3. National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ) Department of Translational Oncology Heidelberg Germany

4. Section for Personalized Oncology University Hospital Heidelberg Heidelberg Germany

5. Department of Pathology University Hospital Heidelberg Heidelberg Germany

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.14664

Reference16 articles.

1. Nonmelanoma skin cancer

2. Skin cancers after organ transplantation – reply;Euvrard S;N Engl J Med,2003

3. Developments in the Treatment of Locally Advanced and Metastatic Squamous Cell Carcinoma of the Skin: A Rising Unmet Need

4. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial

5. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy and Its Timing in Advanced Basal Cell Carcinoma Treatment;Dermatology Practical & Conceptual;2023-10-31

2. Oncological Outcome After Lymph Node Dissection for Cutaneous Squamous Cell Carcinoma;Annals of Surgical Oncology;2023-03-29

3. The current clinical approach to difficult-to-treat basal cell carcinomas;Expert Review of Anticancer Therapy;2023-01-02

4. Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial;European Journal of Cancer;2022-12

5. Molecular Mechanisms and Targeted Therapies of Advanced Basal Cell Carcinoma;International Journal of Molecular Sciences;2022-10-08